Sanofi (SNY) Reports Q3 EPS of EUR1.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sanofi - Q3 2015 Results
October 29, 2015 3:53 AM EDTPARIS, October 29, 2015 /PRNewswire/ --
Sanofi, a global and diversified healthcare leader, reports results for the third quarter of 2015. Jérôme Contamine, Chief Financial Officer of Sanofi, comments on the Group's Q3 results.
Watch video interview and read... More
Sanofi grew sales and business EPS(1) in Q3 2015
October 29, 2015 2:47 AM EDTPARIS, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Group sales(2) increased 3.4% (up 9.2% on a reported basis) to 9,591 million Diabetes sales decreased 6.6%, as a result of lower U.S. sales of Lantus® Genzyme sales (up 32.7%) showed strong momentum driven by Multiple Sclerosis products Vaccines sales were up 5.5% mainly driven by Emerging Markets(3) Animal Health delivered another strong performance (up 9.3%) driven by NexGard® Emerging Markets sales increased by 11.4% Steady financial performance taking into account higher investments in new products
Operating expenses were 3,816m, up 7.5% at CER Business net income grew 5.0% at CER (up 8.3% on a reported basis) to 2,096 million Business EPS increased 6.1%... More
